AKT1 and non-small cell lung carcinoma: For example, Gong et al. 2017 [17] recently described that combined radiotherapy and anti-PD-L1 antibody treatment was able to synergistically enhance the anti-tumor effect in Non-Small Cell Lung Cancer (NSCLC), probably via PI3K/AKT and STAT3 pathways.